MRK · Merck & Co., Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 3, 2021; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| CAPVAXIVE Sales | $184M | FY2026 Q2 | +42.6% |
|
|
|||
| GARDASIL/GARDASIL 9 Sales | $1.17B | FY2026 Q2 | +3.8% |
|
|
|||
| Animal Health Sales | 1.8B | Second Quarter | — |
|
|
|||
| KEYTRUDA QLEX Sales | 463M | Second Quarter | — |
| Non-GAAP gross margin non-GAAP | 81.1% | Second Quarter | — |
|
|
|||
| WINREVAIR Sales | 588M | Second Quarter | — |
| Non-GAAP other (income) expense, net non-GAAP | $318M | first quarter of 2026 | — |
| Non-GAAP R&D expenses non-GAAP | $12.6B | first quarter of 2026 | — |
| Non-GAAP SG&A expenses non-GAAP | $2.7B | first quarter of 2026 | — |
| KEYTRUDA/KEYTRUDA QLEX Sales | $31.7B | Full-Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRK
this stock
Merck & Co., Inc.
|
$379.22B | +45.4% | +1.3% | 123.0 | 1.0% |
|
LLY
ELI LILLY & Co
|
$1.14T | +10.7% | +44.7% | 40.7 | 0.7% |
|
JNJ
Johnson & Johnson
|
$658.24B | +30.5% | +6.0% | 31.7 | 0.9% |
|
ABBV
AbbVie Inc.
|
$467.44B | +15.1% | +8.6% | 74.7 | 1.0% |
|
NVS
Novartis AG
|
$300.03B | +14.3% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 3, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRK | +0.6% | +17.4% | +31.9% | +17.6% | +45.5% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +1.0% | +12.4% | +19.5% | +15.0% | +33.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.